Erythroleukemic Blast Crisis of Chronic Myeloid Leukemia.
10.3343/kjlm.2006.26.4.255
- Author:
Hee Jung CHUNG
1
;
Hyun Sook CHI
;
Eul Ju SEO
;
Seongsoo JANG
;
Chan Jeoung PARK
;
Kyoo Hyung LEE
Author Information
1. Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea. hschi@amc.seoul.kr
- Publication Type:Case Report
- Keywords:
Chronic myeloid leukemia;
Erythroleukemic blast crisis;
Imatinib resistance
- MeSH:
Blast Crisis*;
Bone Marrow;
Bone Marrow Transplantation;
Diagnosis;
Glycophorin;
Graft vs Host Disease;
Granulocyte Precursor Cells;
Humans;
Immunophenotyping;
Karyotype;
Karyotyping;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*;
Polymerase Chain Reaction;
Prognosis;
RNA, Messenger;
Shock, Septic;
Dasatinib;
Imatinib Mesylate
- From:The Korean Journal of Laboratory Medicine
2006;26(4):255-262
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Erythroleukemic blast crisis of chronic myeloid leukemia (CML) is very rare. We report two cases of erythroleukemic blast crisis of CML resistant to imatinib treatment. Both patients made a rapid progression to blast crisis 6 and 4 months after diagnosis while being treated with imatinib 400 mg/day. Bone marrow aspiration revealed predominant erythroid precursors with 65.4% and 54.8% each. There were significant proportions (more than 20%) of myeloblasts among non-erythroid cells. Immunophenotyping revealed expression of glycophorin A confirming erythroleukemic blast crisis. The karyotyping result of patient 1 was 46,XX,t(9;22)(q34;q11.2)[3]/52,idem,+8,+12,+18,+21,+22,+der(22)t(9;22)[17] and that of patient 2 was 46,XX,inv(3)(q21q26.2),t(9;22)(q34;q11.2)[20]. Patient 1 showed no response to imatinib and BMS-354825 in the following bone marrow study. She died of septic shock as a complication of an infection after 69 days of blast crisis. Patient 2 received allogeneic bone marrow transplantation (BMT) in the cytogenetically no response state, but she also died of graft-versus-host disease 9 weeks after BMT. The poor prognosis and rapid progression of disease in both cases were correspondent to most of the reported cases. During the course of the disease of the two patients, we monitored the BCR-ABL chimeric mRNA with real-time quantitative polymerase chain reaction (RT-PCR), and it was found useful in predicting the imatinib response and progression to blast crisis of CML. Although both of our cases showed the typical bad prognosis and findings of erythroleukemic blast crisis of CML, the karyotypes were different from the expected type of t(3;21)(q26;q22). But the relationship between additional changes of EVI1 on chromosome 3q26 shown in case 2, and progression to the erythroleukemic blast crisis need further investigation.
